Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation

被引:5
|
作者
Samaras, Athanasios [1 ]
Vrana, Eleni [1 ]
Kartas, Anastasios [1 ]
Moysidis, Dimitrios, V [1 ]
Papazoglou, Andreas S. [1 ]
Doundoulakis, Ioannis [1 ]
Fotos, George [1 ]
Rampidis, Georgios [1 ]
Tsalikakis, Dimitrios G. [2 ]
Efthimiadis, Georgios [1 ]
Karvounis, Haralambos [1 ]
Tzikas, Apostolos [1 ,3 ]
Giannakoulas, George [1 ]
机构
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Cardiol 1, St Kiriakidi 1, Thessaloniki 54636, Greece
[2] Univ Western Macedonia, Dept Informat & Telecommun Engn, Kozani, Greece
[3] Interbalkan European Med Ctr, Thessaloniki, Greece
关键词
Valvular heart disease; Stenosis; Regurgitation; Atrial fibrillation; Prognosis; Outcomes; THROMBOEMBOLIC EVENTS; ANTICOAGULATED PATIENTS; MITRAL REGURGITATION; EUROPEAN ASSOCIATION; ORAL ANTICOAGULANTS; VALVE DISEASE; WARFARIN; AF; EPIDEMIOLOGY; OUTCOMES;
D O I
10.1186/s12872-021-02264-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Valvular heart disease (VHD) in non-valvular atrial fibrillation (AF) is a puzzling clinical entity. The aim of this study was to evaluate the prognostic effect of significant VHD (sVHD) among patients with non-valvular AF. Methods This is a post-hoc analysis of the MISOAC-AF trial (NCT02941978). Consecutive inpatients with non-valvular AF who underwent echocardiography were included. sVHD was defined as the presence of at least moderate aortic stenosis (AS) or aortic/mitral/tricuspid regurgitation (AR/MR/TR). Cox regression analyses with covariate adjustments were used for outcome prediction. Results In total, 983 patients with non-valvular AF (median age 76 [14] years) were analyzed over a median follow-up period of 32 [20] months. sVHD was diagnosed in 575 (58.5%) AF patients. sVHD was associated with all-cause mortality (21.6%/yr vs. 6.5%/yr; adjusted HR [aHR] 1.55, 95% confidence interval [CI] 1.17-2.06; p = 0.02), cardiovascular mortality (16%/yr vs. 4%/yr; aHR 1.70, 95% CI 1.09-2.66; p = 0.02) and heart failure-hospitalization (5.8%/yr vs. 1.8%/yr; aHR 2.53, 95% CI 1.35-4.63; p = 0.02). The prognostic effect of sVHD was particularly evident in patients aged < 80 years and in those without history of heart failure (p for interaction < 0.05, in both subgroups). After multivariable adjustment, moderate/severe AS and TR were associated with mortality, while AS and MR with heart failure-hospitalization. Conclusion Among patients with non-valvular AF, sVHD was highly prevalent and beared high prognostic value across a wide spectrum of clinical outcomes, especially in patients aged < 80 years or in the absence of heart failure. Predominantly AS, as well as MR and TR, were associated with worse prognosis.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [41] Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study
    Özcan Başaran
    Volkan Dogan
    Osman Beton
    Mehmet Tekinalp
    Ahmet Çağrı Aykan
    Ezgi Kalaycıoğlu
    Ismail Bolat
    Onur Taşar
    Özgen Şafak
    Macit Kalçık
    Mehmet Yaman
    Sinan İnci
    Bernas Altıntaş
    Sedat Kalkan
    Cevat Kırma
    Murat Biteker
    Journal of Thrombosis and Thrombolysis, 2017, 43 : 157 - 165
  • [42] Prognostic Implications of Traditional and Non-traditional Cardiovascular Risk Factor Profiles in Patients With Non-valvular Atrial Fibrillation
    Bhat, Aditya
    Gan, Gary
    Chen, Henry
    Khanna, Shaun
    Nawaz, Sumreen
    MacIntyre, C. Raina
    Tan, Timothy
    CIRCULATION, 2020, 142
  • [43] Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study
    Basaran, Ozcan
    Dogan, Volkan
    Beton, Osman
    Tekinalp, Mehmet
    Aykan, Ahmet Cagri
    Kalaycioglu, Ezgi
    Bolat, Ismail
    Tasar, Onur
    Safak, Ozgen
    Kalcik, Macit
    Yaman, Mehmet
    Inci, Sinan
    Altintas, Bernas
    Kalkan, Sedat
    Kirma, Cevat
    Biteker, Murat
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (02) : 157 - 165
  • [44] Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban
    Mapelli, Massimo
    Mattavelli, Irene
    Salvioni, Elisabetta
    Capra, Nicolo
    Bonomi, Alice
    Cattadori, Gaia
    Pezzuto, Beatrice
    Campodonico, Jeness
    Piotti, Arianna
    Nava, Alessandro
    Piepoli, Massimo
    Magri, Damiano
    Paolillo, Stefania
    Corra, Ugo
    Raimondo, Rosa
    Lagioia, Rocco
    Vignati, Carlo
    Badagliacca, Roberto
    Filardi, Pasquale Perrone
    Senni, Michele
    Correale, Michele
    Cicoira, Mariantonietta
    Metra, Marco
    Guazzi, Marco
    Limongelli, Giuseppe
    Parati, Gianfranco
    De Martino, Fabiana
    Bandera, Francesco
    Bussotti, Maurizio
    Re, Federica
    Lombardi, Carlo M.
    Scardovi, Angela B.
    Sciomer, Susanna
    Passantino, Andrea
    Emdin, Michele
    Santolamazza, Caterina
    Perna, Enrico
    Passino, Claudio
    Sinagra, Gianfranco
    Agostoni, Piergiuseppe
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [45] Prognostic implications of traditional and non-traditional cardiovascular risk factor profiles in patients with non-valvular atrial fibrillation
    Bhat, Aditya
    Gan, Gary C. H.
    Chen, Henry H. L.
    Nawaz, Sumreen
    Khanna, Shaun
    Dobbins, Timothy
    Tan, Timothy C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52 (09)
  • [46] Left atrial appendage occlusion in non-valvular atrial fibrillation
    McCabe, Dominick J. H.
    Kinsella, Justin A.
    Tobin, W. Oliver
    LANCET, 2009, 374 (9689): : 504 - 506
  • [47] Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial)
    Bunch, Thomas Jared
    May, Heidi
    Cutler, Michael
    Woller, Scott C.
    Jacobs, Victoria
    Stevens, Scott M.
    Carlquist, John
    Knowlton, Kirk U.
    Muhlestein, Joseph B.
    Steinberg, Benjamin A.
    Anderson, Jeffrey L.
    JOURNAL OF ARRHYTHMIA, 2022, 38 (06) : 997 - 1008
  • [48] Anticoagulation in patients with non-valvular atrial fibrillation (nvAF) and chronic kidney disease (CKD)
    Zeymer, Uwe
    Bonnemeier, Hendrik
    Wanner, Christoph
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (23) : 1642 - 1649
  • [49] Left atrial appendage closure in non-valvular atrial fibrillation
    Haeusler, K. G.
    Landmesser, U.
    HERZ, 2019, 44 (04) : 310 - 314
  • [50] PROGNOSIS AND THERAPEUTIC EFFECT OF ATORVASTATIN ON PAROXYSMAL ATRIAL FIBRILLATION IN PATIENTS WITH NON-VALVULAR DISEASE
    Liao Wei
    Li Faquan
    Zhang Yixiao
    HEART, 2011, 97 : A208 - A208